Ludovic Bigot, Jonathan Sabio, Loic Poiraudeau, Maxime Annereau, Naoual Menssouri, Carole Helissey, Olivier Déas, Marine Aglave, Tony Ibrahim, Cédric Pobel, Catline Nobre, Claudio Nicotra, Maud Ngo-Camus, Ludovic Lacroix, Etienne Rouleau, Lambros Tselikas, Jean-Gabriel Judde, Anne Chauchereau, Alice Bernard-Tessier, Anna Patrikidou, Natacha Naoun, Ronan Flippot, Emeline Colomba, Alina Fuerea, Laurence Albiges, Pernelle Lavaud, Christophe Massard, Luc Friboulet, Karim Fizazi, Benjamin Besse, Jean-Yves Scoazec, Yohann Loriot
BACKGROUND: Genomic studies have identified new subsets of aggressive prostate cancer (PCa) with poor prognosis (eg, neuroendocrine prostate cancer [NEPC], PCa with DNA damage response [DDR] alterations, or PCa resistant to androgen receptor pathway inhibitors [ARPIs]). Development of novel therapies relies on the availability of relevant preclinical models. OBJECTIVE: To develop new preclinical models (patient-derived xenograft [PDX], PDX-derived organoid [PDXO], and patient-derived organoid [PDO]) representative of the most aggressive variants of PCa and to develop a new drug evaluation strategy...
October 26, 2023: European Urology Oncology